FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to organic chemistry, namely to a compound of formula I and to their pharmaceutically acceptable salt or their ester, wherein W means C(H)2, C(H)2-C(H)2 or C(H)(CH3); X is specified in a group consisting of: (1) O, (2) N(H), (4) S, (5) S(O) and (6) S(O)2; Y means carbon or nitrogen; R1 is specified in a group consisting of: (1) hydrogen, (2) halogen, (3) methyl optionally substituted by fluorine, (4) C1-7alkoxygroup optionally substituted by fluorine, (5) cyano group and (6) C1-7alkylsulphonyl; R2 means hydrogen, fluorine, chlorine or C1-7alkoxygroup; R3 means hydrogen, fluorine, chlorine, bromine or methyl; R4 is specified in a group consisting of: (1) hydrogen, (2) halogen, (3) C1-7alkyl optionally substituted by fluorine, (4) C3-7cycloalkyl, and (5) ethenyl; R5 and R6 are independently from each other specified in a group consisting of: (1) hydrogen, (2) halogen, (3) C1-7alkyl, (4) cyanogroup and (5) C3-7cycloalkyl; R7 means cyano group or S(O)2-R8, wherein R8 is specified in a group consisting of: (1) C1-7alkyl, (2) C3-7cycloalkyl, (4) C1-7alkylamino group, (5) C1-7dialkylamino group, (6) lower heterocycloalkyl optionally substituted by halogen, C1-7alkyl, or C1-7alkoxycarbonyl and (7) 2-oxa-6-azaspiro[3.3]hept-6-yl, wherein lower heterocycloalkyl means a saturated or partially unsaturated non-aromatic ring fragment containing 3 to 7 atoms bound together to form a ring structure, wherein one, two or three ring atoms are heteroatoms, whereas the rest ring atoms are carbon atoms; and pharmaceutically acceptable esters represent methyl and ethyl acid esters of formula I acceptable as prodrugs. The invention also refers to a pharmaceutical composition based on the compound of formula 
.
EFFECT: prepared are new compounds possessing the CRTH2 receptor antagonist or partial agonist activity.
23 cl, 90 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
| DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE-1-YL-UREA AND THEIR USE IN TREATMENT, INTER ALIA, DISEASES OF RESPIRATORY TRACT | 2011 |
|
RU2586333C1 |
| COMPOUNDS AND COMPOSITIONS AS TRO MIMETICS | 2006 |
|
RU2385865C2 |
| KINASE INHIBITORS | 2012 |
|
RU2623734C9 |
| USE OF TRICYCLIC DERIVATIVES OF 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE AND ITS NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND DERIVATIVES OF SUBSTITUTED NAPHTHALENES AS INTERMEDIATE COMPOUNDS | 1996 |
|
RU2178791C2 |
| BENZOTHIAZINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAL DRUGS | 2010 |
|
RU2523791C2 |
| NOVEL COMPOUNDS OF CONDENSED IMIDAZOLE POSSESSING OF CB2 RECEPTOR AGONIST PROPERTY | 2002 |
|
RU2312864C2 |
| BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | 2009 |
|
RU2547441C2 |
| P38 INHIBITORS AND APPLICATION METHODS | 2004 |
|
RU2357957C2 |
| PHENOXYPYRIDINYLAMIDE DERIVATIVES, AND THEIR USE IN TREATMENT OF PDE4-MEDIATED DISEASE STATES | 2009 |
|
RU2509077C2 |
